Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieran F Docherty

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
European Journal of Heart Failure|September 15, 2023
Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESCAntoni Bayes-Genis, Kieran F Docherty, Mark C Petrie, et al.
European Journal of Heart Failure|January 22, 2022
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HFKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
JACC. Asia|November 7, 2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFKieran F Docherty, Inder S Anand, Chern-En Chiang, et al.
Circulation|April 11, 2023
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HFSu Ern Yeoh, Kieran F Docherty, Ross T Campbell, et al.
Circulation. Heart Failure|November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF TrialJawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Circulation|August 26, 2023
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER TrialSafia Chatur, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|March 15, 2025
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HFToru Kondo, Pardeep S Jhund, Inder S Anand, et al.
JAMA Cardiology|March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionKirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
European Journal of Heart Failure|September 15, 2023
Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESCAntoni Bayes-Genis, Kieran F Docherty, Mark C Petrie, et al.
European Journal of Heart Failure|January 22, 2022
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HFKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
JACC. Asia|November 7, 2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFKieran F Docherty, Inder S Anand, Chern-En Chiang, et al.
Circulation|April 11, 2023
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HFSu Ern Yeoh, Kieran F Docherty, Ross T Campbell, et al.
Circulation. Heart Failure|November 22, 2021
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF TrialJawad H Butt, Carly Adamson, Kieran F Docherty, et al.
Circulation|August 26, 2023
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER TrialSafia Chatur, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|March 15, 2025
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HFToru Kondo, Pardeep S Jhund, Inder S Anand, et al.
JAMA Cardiology|March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionKirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
Annals of Internal Medicine|April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF TrialJawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology|March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure TrialJawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Pageof 15